Research Articles

2020  |  Vol: 6(1)  |  Issue: 1 (January-February)  |
Effects of Atorvastatin and Rosuvastatin on glycemic parameters of dyslipidemic patients: A prospective study

Shamshi Azmi1, Jameel Ahmad1*, Farida Ahmad1, Anjum M Chughtai2

1Department of Pharmacology, JNMC AMU Aligarh (U.P.) India

2Department of Pharmacology and Medicine, JNMC AMU Aligarh (U.P.) India

*Address for Corresponding Author

Jameel Ahmad

Department of pharmacology, JNMC AMU Aligarh (U.P.) India



Objective: In the recent past, there were several reports of increased risk of type 2 Diabetes Mellitus with the use of statins. Therefore randomized, prospective, parallel group, open labeled, 24 weeks study of Atorvastatin and Rosuvastatin was done on newly diagnosed cases of dyslipidemia. Methods: This pre-specified analysis was conducted after the last patient completed 24 weeks. Eligible patients were randomized into two groups Group-1 (Atorvastatin) and Group-2 (Rosuvastatin). The two groups were further divided into subgroups based on different doses. At week 24, statistically significant increase in fasting plasma glucose, 2 hour post prandial plasma glucose and haemoglobin A1c was observed with Atorvastatin 10 and 20 mg, and Rosuvastatin 5 and 10 mg. Results: Statins were well tolerated with no evidence of any severe adverse event. Atorvastatin and Rosuvastatin showed an increase in all glycemic parameters (FPG, 2hours PPG, HbA1c); yet none of the subjects entered into overt diabetic range during our study period. Conclusion: Atorvastatin and Rosuvastatin showed an increase in all glycemic parameters (FPG, 2 hours PPG, HbA1c).

Keywords: Atorvastatin, rosuvastatin, glycemic parameters, HbA1C, dyslipidemia

Manuscript Management System
Submit Article Subscribe Most Popular Articles Join as Reviewer Email Alerts Open Access
Our Another Journal
Another Journal
Call for Paper in Special Issue on

Call for Paper in Special Issue on